Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
108.3 USD | -1.56% |
|
+1.10% | +72.88% |
06-27 | Natera Launches Phase 2 Gastroesophageal Cancer Trial Using Signatera | MT |
06-27 | Natera, Inc. Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+72.88% | 13.3B | |
+18.69% | 84.15B | |
-25.20% | 74.14B | |
+1.13% | 26.77B | |
-10.46% | 17.15B | |
+0.86% | 16.83B | |
-0.73% | 15.21B | |
+76.04% | 12.99B | |
-25.96% | 12.79B | |
+21.31% | 12.38B |
- Stock Market
- Equities
- NTRA Stock
- News Natera, Inc.
- Transcript : Natera, Inc. Presents at JPMorgan 40th Annual Healthcare Conference, Jan-10-2022 04